PLEGRIDY® (Peginterferon Beta-1a) Three-Year Data Presented at AAN Annual Meeting Support Long-Term Safety and Efficacy in Multiple Sclerosis Patients

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to PLEGRIDY® (Peginterferon Beta-1a) Three-Year Data Presented at AAN Annual Meeting Support Long-Term Safety and Efficacy in Multiple Sclerosis Patients

Baird Remains Buyers of Biogen (BIIB) Despite Kyle Bass Tecfidera Challenge

April 22, 2015 3:50 PM EDT

Baird analyst Christopher Raymond weighed in on Biogen (NASDAQ: BIIB) this afternoon following news hedge fund manager Kyle Bass has filed an IPR against a Tecfidera patent.

The analyst said the challenge does not come as a surprise and they predicted this in February after... More

Kyle Bass files challenge to Biogen (BIIB) patent on Tecfidera - Bloomberg

April 22, 2015 11:13 AM EDT

Kyle Bass files challenge to Biogen (NASDAQ: BIIB) patent on Tecfidera - Bloomberg

... More